Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 1;1(1):e000013. doi: 10.1136/lupus-2014-000013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

PMC Copyright notice

Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Representative antiphosphotyrosine blots from experiments comparing the effect of growing podocytes for 24 h in normal control (NC) plasma versus plasma from patients with LN (A), rheumatoid arthritis (RA, B) or non-renal systemic lupus erythematosus (NR-SLE, C). Cells were lysed and protein tyrosine phosphorylation assessed by western blot. The graphs display densitometry, with the median and IQR for each group. Medians were compared using the Mann–Whitney test. As already shown, LN plasma leads to a reduction in protein tyrosine phosphorylation, whereas the effect of plasma from patients with RA or NR-SLE is no different to NC. Equal loading was ensured by blotting for either actin or GAPDH.